High-Dose Oral Insulin and the Quest for Primary Prevention
Type 1 diabetes (T1D) remains one of the most challenging chronic conditions of childhood, characterized by the autoimmune destruction of insulin-producing pancreatic beta cells. For decades, the medical community has sought a ‘holy grail’ in pediatric endocrinology: a way to prevent the autoimmune process before it begins. The Primary Oral Insulin Trial (POInT), a large-scale, European, multicenter, randomized, placebo-controlled trial, recently published in The Lancet, investigated whether the early introduction of oral insulin could induce immunological tolerance and prevent the development of islet autoimmunity in genetically predisposed infants.
